Medical device shortages in 2026 remain a serious sourcing concern for hospitals, distributors and procurement teams. The latest U.S. Food and Drug Administration shortage data shows that several critical product categories are expected to remain constrained through late 2026 or even into the first quarter of 2027 (FDA, June 2026).
The situation is also a reminder that shortages do not always begin with insufficient manufacturing capacity. Component failures, supplier interruptions, recalls and the discontinuation of specific products can quickly reduce the number of available sourcing options.
Which medical devices are currently in shortage?
As of the FDA's June 16, 2026 update, six product codes remained on the Medical Device Shortages List. Several are used in specialized surgical and cardiovascular procedures where substitution can be difficult.
Neurosurgical patties, sponges and strips: Products under FDA code HBA are expected to remain in shortage through the fourth quarter of 2026. The disruption followed supplier issues involving neurosurgical patties and related products (FDA, May 2026).
The FDA reported that Medline Industries had identified higher-than-expected endotoxin levels in certain neurosurgical pattie products and initiated a recall of affected neuro sponge SKUs. Healthcare facilities were advised to prioritize essential procedures, control inventory and diversify appropriate supply sources (FDA, May 2026).
Stereotactic breast biopsy needles: Product code KNW remains under particular pressure, with the FDA estimating that the shortage could continue through the end of March 2027 (FDA, June 2026).
The disruption followed supplier issues and the removal of certain Hologic Brevera Breast Biopsy System disposable needles after concerns that metal or plastic particles could become dislodged during use. The FDA has specifically recommended expanding supplier networks and diversifying available needle gauges and lengths where clinically appropriate (FDA, June 2026).
Cardiovascular and surgical devices face longer disruptions
Endoscopic vessel harvesting systems under product code GEI remain on the shortage list, with availability constraints now expected through Q1 2027. These systems are used to harvest blood vessels during procedures such as coronary artery bypass surgery.
The category has faced repeated availability concerns since 2024. In 2026, the FDA also reported recalls affecting certain VasoView HemoPro systems, adding another layer of supply-chain complexity for healthcare providers relying on these devices (FDA, July 2026).
Oxygenator devices used for extracorporeal circulation are another persistent problem. Both long-term support oxygenators under product code BYS and cardiopulmonary bypass oxygenators under code DTZ are expected to remain in shortage through Q1 2027. In both cases, the reported reason is a shortage or discontinuance involving a component, part or accessory (FDA, June 2026).
Angiographic syringes remain a near-term procurement risk
Angiographic control syringes with rotating adapters, classified under product code DXT, were estimated to remain in shortage through the third quarter of 2026. Although the anticipated disruption is shorter than for several surgical products, buyers should continue monitoring available inventory and supplier lead times.
The FDA again identifies disruption to a component, part or accessory as the underlying cause. This pattern demonstrates how dependence on relatively small components can constrain the supply of a much larger finished medical device.
Discontinued products can create hidden supply gaps
Shortage lists tell only part of the story. The FDA also maintains a separate medical device discontinuance list, which received additional entries in June 2026 across categories including anesthesiology, cardiovascular devices, gastroenterology, surgery and diagnostics.
Recent examples include respiratory accessories, cardiopulmonary bypass components, sutures and other specialized products. A discontinuation does not automatically create a market-wide shortage, but it can cause significant problems for individual hospitals or distributors that rely heavily on a particular SKU or manufacturer.
What procurement teams should do now
The most important lesson from the 2026 shortage data is diversification. Buyers should identify technically suitable alternative manufacturers before existing stock reaches a critical level and determine whether alternative products meet required specifications, certifications and clinical requirements.
Procurement teams should also monitor manufacturer discontinuation notices, maintain visibility into consumption rates and avoid treating a confirmed purchase order as proof of long-term supply security. For critical devices, a secondary sourcing route should be documented alongside the primary supplier.
Medical device shortages can develop quickly when a recall, component failure or supplier interruption removes capacity from a concentrated market. Building broader manufacturer visibility before a disruption occurs gives procurement teams more time to compare alternatives and reduce dependency on a single source.
Suplivia's sourcing network covers more than 200,000 medical products from 10,000 manufacturers across 80 countries, helping procurement professionals identify relevant manufacturers, alternative products and sourcing options across multiple markets when existing supply routes become constrained.
